123 related articles for article (PubMed ID: 23308047)
1. MicroRNA expression profiling of peripheral blood samples predicts resistance to first-line sunitinib in advanced renal cell carcinoma patients.
Gámez-Pozo A; Antón-Aparicio LM; Bayona C; Borrega P; Gallegos Sancho MI; García-Domínguez R; de Portugal T; Ramos-Vázquez M; Pérez-Carrión R; Bolós MV; Madero R; Sánchez-Navarro I; Fresno Vara JA; Espinosa Arranz E
Neoplasia; 2012 Dec; 14(12):1144-52. PubMed ID: 23308047
[TBL] [Abstract][Full Text] [Related]
2. Prognostic stratification of patients with advanced renal cell carcinoma treated with sunitinib: comparison with the Memorial Sloan-Kettering prognostic factors model.
Bamias A; Karadimou A; Lampaki S; Lainakis G; Malettou L; Timotheadou E; Papazisis K; Andreadis C; Kontovinis L; Anastasiou I; Stravodimos K; Xanthakis I; Skolarikos A; Christodoulou C; Syrigos K; Papandreou C; Razi E; Dafni U; Fountzilas G; Dimopoulos MA
BMC Cancer; 2010 Feb; 10():45. PubMed ID: 20163744
[TBL] [Abstract][Full Text] [Related]
3. Sunitinib re-challenge in advanced renal-cell carcinoma.
Porta C; Paglino C; Grünwald V
Br J Cancer; 2014 Sep; 111(6):1047-53. PubMed ID: 24800947
[TBL] [Abstract][Full Text] [Related]
4. Large-scale genome-wide screening of circulating microRNAs in clear cell renal cell carcinoma reveals specific signatures in late-stage disease.
Chanudet E; Wozniak MB; Bouaoun L; Byrnes G; Mukeriya A; Zaridze D; Brennan P; Muller DC; Scelo G
Int J Cancer; 2017 Nov; 141(9):1730-1740. PubMed ID: 28639257
[TBL] [Abstract][Full Text] [Related]
5. Circulating microRNAs from the Molecular Mechanisms to Clinical Biomarkers: A Focus on the Clear Cell Renal Cell Carcinoma.
Tito C; De Falco E; Rosa P; Iaiza A; Fazi F; Petrozza V; Calogero A
Genes (Basel); 2021 Jul; 12(8):. PubMed ID: 34440329
[TBL] [Abstract][Full Text] [Related]
6. Candidate biomarkers for treatment benefit from sunitinib in patients with advanced renal cell carcinoma using mass spectrometry-based (phospho)proteomics.
van der Wijngaart H; Beekhof R; Knol JC; Henneman AA; de Goeij-de Haas R; Piersma SR; Pham TV; Jimenez CR; Verheul HMW; Labots M
Clin Proteomics; 2023 Nov; 20(1):49. PubMed ID: 37940875
[TBL] [Abstract][Full Text] [Related]
7. Integration analysis of PLAUR as a sunitinib resistance and macrophage related biomarker in ccRCC, an in silicon and experimental study.
Yang Q; Ye F; Li L; Chu J; Tian Y; Cao J; Gan S; Jiang A
J Biomol Struct Dyn; 2024 Jan; ():1-18. PubMed ID: 38173169
[TBL] [Abstract][Full Text] [Related]
8. Identification of tissue microRNAs predictive of sunitinib activity in patients with metastatic renal cell carcinoma.
Prior C; Perez-Gracia JL; Garcia-Donas J; Rodriguez-Antona C; Guruceaga E; Esteban E; Suarez C; Castellano D; del Alba AG; Lozano MD; Carles J; Climent MA; Arranz JA; Gallardo E; Puente J; Bellmunt J; Gurpide A; Lopez-Picazo JM; Hernandez AG; Mellado B; Martínez E; Moreno F; Font A; Calvo A
PLoS One; 2014; 9(1):e86263. PubMed ID: 24475095
[TBL] [Abstract][Full Text] [Related]
9. Integrated genomic analysis identifies subclasses and prognosis signatures of kidney cancer.
Christinat Y; Krek W
Oncotarget; 2015 Apr; 6(12):10521-31. PubMed ID: 25826081
[TBL] [Abstract][Full Text] [Related]
10. Predictive biomarkers in renal cell cancer: insights in drug resistance mechanisms.
van der Mijn JC; Mier JW; Broxterman HJ; Verheul HM
Drug Resist Updat; 2014; 17(4-6):77-88. PubMed ID: 25457974
[TBL] [Abstract][Full Text] [Related]
11. Resistance to sunitinib in renal cell carcinoma: From molecular mechanisms to predictive markers and future perspectives.
Joosten SC; Hamming L; Soetekouw PM; Aarts MJ; Veeck J; van Engeland M; Tjan-Heijnen VC
Biochim Biophys Acta; 2015 Jan; 1855(1):1-16. PubMed ID: 25446042
[TBL] [Abstract][Full Text] [Related]
12. MicroRNA modulation combined with sunitinib as a novel therapeutic strategy for pancreatic cancer.
Passadouro M; Pedroso de Lima MC; Faneca H
Int J Nanomedicine; 2014; 9():3203-17. PubMed ID: 25061297
[TBL] [Abstract][Full Text] [Related]
13. Resistance to tyrosine kinase inhibitors in clear cell renal cell carcinoma: from the patient's bed to molecular mechanisms.
Buczek M; Escudier B; Bartnik E; Szczylik C; Czarnecka A
Biochim Biophys Acta; 2014 Jan; 1845(1):31-41. PubMed ID: 24135488
[TBL] [Abstract][Full Text] [Related]
14. Micro-RNAs Predict Response to Systemic Treatments in Metastatic Renal Cell Carcinoma Patients: Results from a Systematic Review of the Literature.
Monti M; Lunardini S; Magli IA; Campi R; Primiceri G; Berardinelli F; Amparore D; Terracciano D; Lucarelli G; Schips L; Ferro M; Marchioni M
Biomedicines; 2022 May; 10(6):. PubMed ID: 35740309
[TBL] [Abstract][Full Text] [Related]
15. The Role of Circulating Biomarkers in the Oncological Management of Metastatic Renal Cell Carcinoma: Where Do We Stand Now?
Cinque A; Capasso A; Vago R; Lee MW; Floris M; Trevisani F
Biomedicines; 2021 Dec; 10(1):. PubMed ID: 35052770
[TBL] [Abstract][Full Text] [Related]
16. Integrated mRNA and miRNA Transcriptomic Analyses Reveals Divergent Mechanisms of Sunitinib Resistance in Clear Cell Renal Cell Carcinoma (ccRCC).
Armesto M; Marquez M; Arestin M; Errarte P; Rubio A; Manterola L; López JI; Lawrie CH
Cancers (Basel); 2021 Aug; 13(17):. PubMed ID: 34503211
[TBL] [Abstract][Full Text] [Related]
17. MicroRNAs Targeting HIF-2α, VEGFR1 and/or VEGFR2 as Potential Predictive Biomarkers for VEGFR Tyrosine Kinase and HIF-2α Inhibitors in Metastatic Clear-Cell Renal Cell Carcinoma.
Kinget L; Roussel E; Verbiest A; Albersen M; Rodríguez-Antona C; Graña-Castro O; Inglada-Pérez L; Zucman-Rossi J; Couchy G; Job S; de Reyniès A; Laenen A; Baldewijns M; Beuselinck B
Cancers (Basel); 2021 Jun; 13(12):. PubMed ID: 34205829
[TBL] [Abstract][Full Text] [Related]
18. Epigenetic Alterations in Renal Cell Cancer With TKIs Resistance: From Mechanisms to Clinical Applications.
Li Q; Zhang Z; Fan Y; Zhang Q
Front Genet; 2020; 11():562868. PubMed ID: 33510766
[TBL] [Abstract][Full Text] [Related]
19. Circulating Non-coding RNAs in Renal Cell Carcinoma-Pathogenesis and Potential Implications as Clinical Biomarkers.
Barth DA; Drula R; Ott L; Fabris L; Slaby O; Calin GA; Pichler M
Front Cell Dev Biol; 2020; 8():828. PubMed ID: 33042985
[TBL] [Abstract][Full Text] [Related]
20. MicroRNA expression profiles in molecular subtypes of clear-cell renal cell carcinoma are associated with clinical outcome and repression of specific mRNA targets.
Verbiest A; Van Hoef V; Rodriguez-Antona C; García-Donas J; Graña-Castro O; Albersen M; Baldewijns M; Laenen A; Roussel E; Schöffski P; Wozniak A; Caruso S; Couchy G; Zucman-Rossi J; Beuselinck B
PLoS One; 2020; 15(9):e0238809. PubMed ID: 32915890
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
